Figure 4

TOP2A and β-tubulin combination index predicts response to multi-agent anthracycline/taxane chemotherapy. A) Individual target index scores ( A: TOP2A index, T: β-tubulin index) in patients who experienced complete pathological response or had residual disease after TFAC neoadjuvant chemotherapy (GSE21094, p < 0.0001 both cases, t-test). B) ROC analysis of combination index scores and response to TFAC neoadjuvant chemotherapy (AUC: 0.78, p < 0.0001). C) Combination index scores in patients who experienced pCR or had RD after neoadjuvant chemotherapy ( p < 0.0001, t-test). D) Individual target index scores of patients who experienced pCR or had RD after AT neoadjuvant chemotherapy (GSE25055, p < 0.0001 both cases, t-test). E) ROC Analysis of combination index scores and response to AT neoadjuvant chemotherapy for GSE25055 (AUC: 0.78, p < 0.0001). F) Combination index scores of patients who experienced pCR or had RD after AT neoadjuvant chemotherapy ( p <0.0001, t-test). G) Individual target index scores of patients who experienced pCR or had RD after AT neoadjuvant chemotherapy (GSE25065, p < 0.0001 both cases, t-test). H) ROC analysis of combination index scores and response to AT neoadjuvant chemotherapy for GSE25065 (AUC: 0.75, p < 0.0001). I) Combination index scores of patients who experienced complete pathological response or had residual disease after AT neoadjuvant chemotherapy ( p < 0.0001, t-test).